Acute issues of drug supply of the country will be discussed in Kaliningrad

Acute issues of drug supply of the country will be discussed in Kaliningrad 15 September 2020

The partnering "Medicines of Russia - for an interdisciplinary dialogue" will take place on September 25 in Kaliningrad. The focus is on the results of the implementation of the Pharma 2020 strategy, the modernization of the drug supply system, pilot projects for drug reimbursement, the availability and safety of drugs, fair competition in the pharmaceutical market. Now, these and other issues will be discussed at the meeting in the amber capital and online by heads of federal and regional authorities, leading experts of the pharmaceutical industry, managers and specialists of pharmaceutical industries, representatives of professional associations and communities.

The pharmaceutical industry has been at the forefront of the fight against COVID-19. Enterprises have switched to a round-the-clock operation so that citizens are provided with all the necessary medicines. Domestic pharma is represented today not only in Russia, but also in the EurAsEC countries. During this difficult period, joint government and business measures prevented critical disruptions in the production and supply of drugs.

The development of the pharmaceutical industry and ensuring the availability of medicines for patients is one of the main tasks today. Success in solving these large-scale tasks depends on the constructive and fruitful interaction of authorities at all levels, scientific, expert circles and business communities to find effective solutions for the development of the pharmaceutical industry.

As before, the key topic of the Partnering is “Procurement of Medicines under Federal Law No. 44”. The Government of the Russian Federation is creating a federal center for planning and organizing drug supply for citizens, which will purchase drugs for the implementation of the national project "Healthcare", federal projects and programs. A centralized procurement system will help to significantly save the total health budget and prevent interruptions in the supply of drugs, as well as form a drug reserve. To date, procurements require the organization of tens of thousands of tenders of various levels, which spend a lot of money. Often auctions are thwarted and patients are left without drugs. So, in the first quarter of 2020, 93.2 thousand tenders were announced for the purchase of drugs in the amount of 179.5 billion rubles, of which 24.1 thousand were not held. According to the Cursor Marketing company, the share of failed tenders in the total number of procurements remained almost at the level of the previous year: in 2019 it was 24%, in 2020 - 25%.

Experts see many advantages in the upcoming changes, but there are also risks that must be taken into account. Victor Dmitriev, General Director of the Association of Russian Pharmaceutical Manufacturers, believes that “in procurement, the main focus should be on locally produced products, because the pandemic has shown that in such situations, borders are closed. And no matter how good the contracts with foreign suppliers are, you either get delayed deliveries, or you may not get any drugs at all. "

The partnering "Medicines of Russia - towards interdisciplinary dialogue" is a lively discussion between regulators and manufacturers. Each participant will be able to ask his own question and get a detailed answer. In the course of the dialogue, all acute issues of concern to the professional community, which require both answers and effective solutions, will be considered.

Due to the current epidemic situation associated with the spread of COVID-19, the event will be held in a hybrid format. Speakers will come together at a round table, and participants will be able to join the discussion in a convenient and secure online mode. You can send your questions to the speakers now to the Association's email address: arfp@arfp.ru. Registration for the event is open on the ARPM official website: www.arfp.ru

Together we have succeeded in a lot, but there are ambitious plans and a lot of work for the health of patients ahead!



Return to the list